Abstract
Background: We aimed to study the impact of neoadjuvant chemotherapy to surgery (NCT-S) interval and neoadjuvant radiotherapy (NRT) on pathological complete response (pCR) and overall survival (OS) in pancreatic cancer (pancreatic ductal adenocarcinoma [PDAC]). Methods: National Cancer Data Base (NCDB)–pancreatectomy patients who underwent NCT/NRT were included. The NCT-S interval was divided into time quintiles in weeks: 8 to 11, 12 to 14, 15 to 19, 20 to 29, and >29 weeks. Results: A total of 2093 patients with NCT were included with median follow-up of 74 months and 71% NRT. The pCR rate was 2.1% with higher median OS compared with non-pCR (41 vs 19 months, P =.03). The pCR rate increased with longer NCT-S interval (quintiles: 1%, 1.6%, 1.7%, 3%, and 6%, P 29 weeks (OR = 6.1, 95% CI = 2.02-18.50, P
Author supplied keywords
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Cite
CITATION STYLE
Azab, B., Macedo, F. I., Chang, D., Ripat, C., Franceschi, D., Livingstone, A. S., & Yakoub, D. (2020). The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients. Clinical Medicine Insights: Oncology, 14. https://doi.org/10.1177/1179554920919402
Readers' Seniority
Readers' Discipline
